Seres announces completion of patient enrollment for SERS-155 Phase 1b cohort 2

Seres Therapeutics announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received Allogeneic Hematopoietic Stem Cell Transplantation. “We are pleased to complete enrollment in Cohort 2 of our SER-155 Phase 1b study and are looking forward to a robust dataset late in the third quarter of this year,” said Eric Shaff, President and Chief Executive Officer of Seres. “The initial study data will include safety, drug pharmacology, and efficacy-related measures through day 100 following HSCT, a period in which many patients experience infections. There are an estimated 40,000 Allo HSCT procedures annually worldwide and infection is one of the most common causes of mortality in these patients. Our pending clinical results could validate the promise of microbiome therapeutics to prevent poor outcomes associated with pathogens in the GI tract. We intend to evaluate SER-155 and other microbiome therapeutic candidates in several other high prevalence, medically vulnerable patient populations, including chronic liver disease, cancer neutropenia, and solid organ transplants. We envision a future where Seres is pioneering a new standard of care, potentially protecting millions of immunocompromised patients from life-threatening infections.”